Predicting antibiotic combination effects on the selection of resistant Staphylococcus aureus: In vitro model studies with linezolid and gentamicin.
To explore whether combinations of linezolid with gentamicin restrict Staphylococcus aureus resistance, the enrichment of resistant mutants was studied in an in vitro dynamic model. A clinical isolate S. aureus 10 and its linezolid-resistant mutant selected by passaging on antibiotic-containing media were used in the study. The minimum inhibitory concentration (MIC) and the mutant prevention concentration (MPC) of antibiotics in combination were determined at a linezolid-to-gentamicin concentration ratio corresponding to the ratio of 24-h areas under the concentration-time curve (AUC24s) used in the pharmacokinetic simulations. Five-day treatments of S. aureus 10 supplemented with linezolid-resistant mutants (mutation frequency 10-8) with twice-daily linezolid and once-daily gentamicin, alone and in combination, were simulated at therapeutic and subtherapeutic AUC24s. Numbers of linezolid-resistant mutants increased at both therapeutic and subtherapeutic AUC24s, whereas gentamicin-resistant mutants were enriched only at the subtherapeutic AUC24 in single drug treatments. Linezolid-gentamicin combinations prevented the enrichment of linezolid-resistant S. aureus and restricted the enrichment of gentamicin-resistant mutants. The pronounced anti-mutant effect of the combinations was attributed to lengthening the time above MPC of both linezolid and gentamicin as their MPCs were lowered. Unlike resistant S. aureus, killing of the total bacterial burden exposed to linezolid-gentamicin combinations was less than in treatments with gentamicin alone, but greater than with linezolid alone. These findings indicate that (1) the anti-mutant effects of antibiotic combinations can be predicted by MPC determinations at pharmacokinetically-derived concentration ratios, and (2) a given antibiotic combination may be optimal against resistant but not susceptible subpopulations.